Sunday, May 19, 2019
News
NEWS HOME
»
PRESS RELEASES

French Biotech CellVax is Now Able to Propose Preclinical Studies in Large Animals
  SocialTwist Tell-a-Friend  
   


Date: 17-04-2019 11:27AM
Source: CellVax
Category: General, Science & Research, Healthcare & Biotechnology, Medical Devices, Pharmaceutical
Location: Maison-Alfort, France

Business Wire India

  • CellVax announces it has signed strategic partnership with 2 large Chinese pharmaceutical companies: Medtech OSMUNDA, a worldwide leading clinical trial CRO and service provider of medical devices, and big pharmaceutical actor: Guangzhou General Pharmaceutical Research Institute.
  • CellVax is now able to propose to its European customers new standards for preclinical and clinical studies, with large nonrodent animals models
  • Qualifying strategy to meet international standards of scientific quality control
  • Public & private financing underway to support CellVax’s strong growth.

Thanks to this strategic partnership, CellVax can now respond to the strong demand for optimal selection of models that represent the human disease best and is ableto offer preclinical studies in large nonrodent species as well as diversified preclinical models or clinical trials.
Large animal models are essential for the development of novel therapeutics for Cancer and Osteoarthritis (OA) fields, the two research specialties of CellVax. Through this partnership, the company has achieved a significant progress in its capacity to provide wide range of animal models for these diseases.
From now on, CellVax offers to fully realize high value-added projects in China and France / Europe, including product registrations in China for European clients, or a better understanding of European markets for Chinese clients.

Quicker funding to support the growth and to finance quality and R&D resources, innovation driver for CellVax
Since February 2019, CellVax has made a strong commitment to enhance the quality of its preclinical studies. Currently, one large GLP toxicology and Bio-distribution study is ongoing at CellVax.
By the end of 2019, CellVax will be able to perform a full range of GLP-compliant preclinical studies in large and small animals for the development of drugs, vaccines and medical devices.

Furthermore, CellVax is fully invested in numerous large-scale European collaborative research programs such as Eureka, FP-7, and Horizon 2020, as well as in the search for new ways of private / public financing in order to continually enhance its R&D capability and to increase its visibility worldwide.

About CellVax – www.cellvax-pharma.com
Founded in 2001, Cellvax is a preclinical Contract Research Organization (CRO) which provides innovating drug validation studies both in vitro and in vivo allowing to accelerate the drug development process for unmet needs related to severe human diseases, mainly in Cancer and Osteoarthritis fields. In addition to preclinical studies, CellVax provides high quality consulting services in order to optimize the discovery process of candidate compounds.



CONTACTS :

CELLVAX
Dr. Mingxing WEI, CEO
+33 (0) 671434751 (France) +86 182 271 08395 (China)
contact@cellvax-pharma.com

FIN’EXTENSO
Press Relations
Isabelle Aprile
+33 1 39 97 61 22
i.aprile@finextenso.fr

More Press Releases

Traveling for Vacation or Work: Smart Tips That Will Save You Money

Zee Learn FY19 Total Revenue Doubles to Rs 549 Cr; EBITDA at All Time High of Rs 158 Cr

IMS Law College Organized Rural Development Awareness Campaign

London Stock Exchange Welcomes Finablr PLC to the Main Market

Taiwan Expo 2019 Kick-Starts in New Delhi; Expected to Boost Trade Ties Between the Two Countries

Roca’s Innovation Represents 21st Century Toilets Solutions at Sulabh International Museum of Toilets

WIN 2019 Symposium: WINnovation and Global Deployment of Precision Oncology

Bertin Technologies Wins Two Major Contracts for Environmental Radiation Monitoring

Merck Foundation Marks World Hypertension Day 2019 by Their Continuous Programs of Advancing Hypertension and Diabetes Care in African and Asian Countries

Manjula Muthukrishnan Joins Avalara as Managing Director of India

Toshiba Memory and Western Digital to Jointly Invest in Flash Manufacturing Facility in Kitakami, Japan

JPMorgan Chase Bank Launches Offering of Cash-Settled Exchangeable Bonds into Siemens AG Due 2022

Takeda to Showcase Growing Pipeline and Diversified Portfolio of Oncology Products at Upcoming Scientific Congresses

Taro to Announce Full Year Results on May 22, 2019

JPMorgan Chase Bank Announces the Placement of Cash-Settled Exchangeable Bonds into Siemens AG Due 2022

Tokyo Energy & Systems Switches to Rimini Street for SAP Application Support

CEMEX Ventures Invests in Energy Vault to Support Rapid Deployment of Energy Storage Technology Using Concrete Blocks

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Madhya Pradesh: Tribals turn out to vote...
25.25% voting in Bihar LS polls (Lead) (...
Over 45% voting recorded in Panaji bypol...
32% voting in WB amid sporadic violence ...
Poll code violation: TMC complains to EC...
Delhi: Two miscreants killed in exchange...
More...    
 
 Top Stories
Theresa May plans 'bold offer' for ... 
Sushant Pujari on being real street... 
Wearable patch can cool you down on... 
3 NSCN (K) insurgents held in Aruna... 
I don't trust 'Exit Poll gossip', s... 
Priyanka Chopra, Nick Jonas steal s... 
Punjab CEO thanks people for peacef... 
Pak women thrash South Africa women...